Full Breakdown
NHS Rolls Out One-Minute Pembrolizumab Injection for Thousands of Cancer Patients
5/4/2026, 12:30:24 PM
One-Minute Injection Replaces Hour-Long Infusion
The NHS is replacing the intravenous pembrolizumab (Keytruda) infusion with a sub-cutaneous injection that takes one to two minutes. The jab, given every three weeks (one-minute) or six weeks (two-minute), will serve roughly 14,000 patients across 30 cancer types. University Hospitals Bristol, Weston NHS Foundation Trust and East and North Hertfordshire Teaching NHS Trust are among the first providers. Prof Peter Johnson, NHS national clinical director for cancer, oversaw the rollout.
Scale, Savings and Clinical Reach
NHS calculations estimate the new formulation will save over 100,000 hours annually by cutting chair time from about 120 minutes to one or two minutes, increasing chemotherapy unit capacity by up to 30 %. Pembrolizumab generated $30 bn (£22 bn) in sales in 2025 and cumulative sales of $180 bn (£140 bn) since launch.
Official NHS and Industry Responses
NHS England called the change a “win-win innovation” that shortens visits and expands capacity. James Richardson, national specialty adviser for cancer drugs, highlighted gains. Prof Johnson said the jab could free space in chemotherapy units and enable treatment outside hospitals. MSD said the jab offers meaningful benefits for hospitals by reducing administration time.
Patent and Pricing Concerns
Critics, including U.S. Senator Elizabeth Warren, argue MSD’s new formulation extends patent protection and may block cheaper generics. Pembrolizumab patents expire in 2028 in United States and 2031 in Europe, raising affordability concerns. MSD maintains the jab’s clinical advantages justify its price, though NHS has not disclosed the cost.
Transparency Gaps
NHS England declined to reveal the price of injectable pembrolizumab, citing confidentiality of its agreement with MSD. Analysts infer the cost matches the IV product, but the lack of pricing transparency prevents verification of financial savings beyond staff-time efficiencies.
Verbatim Quotes
- “Prof Peter Johnson, the NHS national clinical director for cancer, said: “This immunotherapy offers a lifeline for thousands of patients and it’s fantastic that this new rapid jab can now take just a minute to deliver – meaning patients can get back to living their lives rather than spending hours in a hospital chair.” — Prof Peter Johnson, NHS national clinical director for cancer
- “It's made such a difference and gives me more time to live my life, including spending more time gardening.” — Shirley Xerxes, patient
- “James Richardson, the national specialty adviser for cancer drugs at NHS England, said: “This is a win-win innovation, because patients will spend far less time in hospital and, crucially, our clinical teams will have more capacity to care for others.” — James Richardson, national specialty adviser for cancer drugs, NHS England
- “MSD says the jab offers "meaningful benefits" for hospitals by reducing the time spent administering the drug, freeing up time for other clinical tasks and potentially reducing the pressure on NHS resources.” — MSD spokesperson
Future Rollout
The NHS plans to extend the injectable pembrolizumab to additional trusts over next months and to evaluate community-based delivery models. Patent expirations in 2028 (US) and 2031 (EU) may enable lower-cost generic versions.
